Infinity Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Infinity Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -14.5%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 19.3%. De inkomsten zijn daalde met een gemiddeld percentage van 54% per jaar.

Belangrijke informatie

-14.5%

Groei van de winst

-2.9%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.0%
Inkomstengroei	-54.0%
Rendement op eigen vermogen	n/a
Nettomarge	-1,593.9%
Laatste winstupdate	30 Jun 2023

Recente prestatie-updates uit het verleden

Recent updates

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Nov 10

Infinity Pharmaceuticals: Waiting For A Deal

Sep 08

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

May 23

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Dec 29

Investigating Infinity Pharmaceuticals

Nov 25

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Jul 18

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Apr 13

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Feb 19

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Jan 15

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Jan 06

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Dec 11

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

Dec 09

Infinity Pharmaceutical Reaching Vital New Staging Posts

Dec 01

Opbrengsten en kosten

Hoe Infinity Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

OTCPK:INFI.Q Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 23	3	-41	14	0
31 Mar 23	3	-43	16	0
31 Dec 22	3	-44	13	0
30 Sep 22	3	-47	14	0
30 Jun 22	2	-47	14	0
31 Mar 22	2	-46	14	0
31 Dec 21	2	-45	14	0
30 Sep 21	2	-44	14	0
30 Jun 21	2	-43	13	0
31 Mar 21	2	-41	13	0
31 Dec 20	2	-40	12	0
30 Sep 20	2	-41	13	0
30 Jun 20	1	-43	13	0
31 Mar 20	1	-44	14	0
31 Dec 19	3	-47	14	0
30 Sep 19	3	-44	15	0
30 Jun 19	25	-19	14	0
31 Mar 19	24	-16	14	0
31 Dec 18	22	-11	14	0
30 Sep 18	22	-10	15	0
30 Jun 18	6	-31	16	0
31 Mar 18	6	-41	19	0
31 Dec 17	6	-42	22	0
30 Sep 17	6	-57	24	0
30 Jun 17	0	-70	25	0
31 Mar 17	9	0	30	0
31 Dec 16	19	-30	35	0
30 Sep 16	28	-46	37	0
30 Jun 16	119	15	41	0
31 Mar 16	114	-76	39	0
31 Dec 15	109	-128	37	0
30 Sep 15	104	-129	35	0
30 Jun 15	174	-71	33	0
31 Mar 15	169	-68	31	0
31 Dec 14	165	-17	29	0
30 Sep 14	161	-10	28	100
30 Jun 14	0	-145	28	100
31 Mar 14	0	-142	27	100
31 Dec 13	0	-127	28	0
30 Sep 13	0	-141	27	74
30 Jun 13	0	-88	26	74
31 Mar 13	22	-71	27	74

Kwaliteitswinsten: INFI.Q is momenteel verliesgevend.

Groeiende winstmarge: INFI.Q is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: INFI.Q is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 14.5% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van INFI.Q over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: INFI.Q is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 16.6% ).

Rendement op eigen vermogen

Hoge ROE: De schulden van INFI.Q zijn groter dan de activa, dus het is lastig om het rendement op het eigen vermogen te berekenen.

Infinity Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

Disclosure Statement Approved for Infinity Pharmaceuticals, Inc.

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Nasdaq to Delist the Securities of Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. Filed for Bankruptcy

Infinity Pharmaceuticals, Inc.(OTCPK:INFI) dropped from NASDAQ Composite Index

Infinity Pharmaceuticals Receives Delisting Determination Letter from Nasdaq Regarding Not in Compliance with the Minimum Bid Price Requirement

Infinity Pharmaceuticals Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum MVPHS Requirement

Rosen Law Firm Announces the Filing of A Class Action Lawsuit on Behalf of Purchasers of Securities of Infinity Pharmaceuticals, Inc

Infinity Pharmaceuticals, Inc. Announces Resignation of Samuel Agresta, Sujay R. Kango and Brian Schwartz from Board

MEI Pharma, Inc. (NasdaqCM:MEIP) cancelled the acquisition of Infinity Pharmaceuticals, Inc. (NasdaqGS:INFI) from The Vanguard Group, Inc. and others.

New major risk - Revenue and earnings growth

Infinity Pharmaceuticals, Inc. Provides Additional Information on MARIO-8 Study Evaluating Eganelisib in Combination with the PD-1 Targeted Checkpoint Inhibitor Pembrolizumab (KEYTRUDA®) in Patients with Squamous Cell Cancer of the Head and Neck

Infinity Pharmaceuticals Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased by 20% to US$4.00

Infinity Pharmaceuticals Receives A Deficiency Letter from Nasdaq Regarding Minimum Bid Requirement

Consensus revenue estimates increase by 276%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Infinity Pharmaceuticals: Waiting For A Deal

Consensus estimates of losses per share improve by 10%

Infinity Pharmaceuticals, Inc. Unveils New Positive Data from the Phase 2 MARIO-275 Clinical Trial

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Infinity Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 20%

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$6.67

Infinity Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Consensus revenue estimates increase by 232%

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$9.00

Infinity Pharmaceuticals, Inc. Provides Earning Guidance for 2022

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Price target increased to US$9.71

Infinity Pharmaceuticals, Inc. Announces Encouraging Updated Data from Phase 2 Mario-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium

Investigating Infinity Pharmaceuticals

Third quarter 2021 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2020)

Consensus revenue estimates increase to US$1.89m

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.17 loss in 2Q 2020)

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Consensus forecasts updated

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Consensus forecasts updated

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.19 loss in 1Q 2020)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2021

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Full year 2020 earnings released: US$0.68 loss per share (vs US$0.83 loss in FY 2019)

Infinity Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2021

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Infinity Pharmaceuticals, Inc. Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at Asco Genitourinary Cancers Symposium

New 90-day high: US$5.36

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

New 90-day high: US$2.80

Infinity Pharmaceuticals, Inc. Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Infinity Pharmaceuticals, Inc. Announces Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

New 90-day high: US$2.16

Infinity Pharmaceutical Reaching Vital New Staging Posts

Analysts update estimates

New 90-day high: US$1.51